Using angiogenic immunogenic proteins or disabled immunosuppressant for the production of secretory IgA

摘要

Use, in combination with an adjuvant of mucosal immunity, Tat protein virus HIV1 immunosuppressant cuyaspropiedades and / or angiogenic are disabled at least 70%, for físicoy / or chemical treatment, by genetic recombination or also for adjuvant conditioning, by preserving dichotratamiento the property of being recognized by antibodies directed against said Tat protein, and conservándoleunas sufficient immunogenic properties to create antibodies neutralizing or blocking dichaproteína native Tat, or also the use of a DNA molecule corresponding to said protein Tatdesactivada by mutation or DNA molecule corresponding to said inactive fragment, for obtenciónde a medicament conferring mucosal immunity based on antibody secretion of IgA, parael treatment of cancers associated with infection by the virus HIV-1 .